PolyPid Ltd.

NASDAQ: PYPD · Real-Time Price · USD
2.78
-0.02 (-0.71%)
At close: May 02, 2025, 3:59 PM
2.79
0.50%
After-hours: May 02, 2025, 04:00 PM EDT
-0.71%
Bid 2.5
Market Cap 28.29M
Revenue (ttm) n/a
Net Income (ttm) -29.02M
EPS (ttm) -4.91
PE Ratio (ttm) -0.57
Forward PE -2.34
Analyst Buy
Ask 3.08
Volume 3,699
Avg. Volume (20D) 13,590
Open 2.80
Previous Close 2.80
Day's Range 2.73 - 2.87
52-Week Range 2.30 - 4.94
Beta 1.28

About PYPD

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is head...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 57
Stock Exchange NASDAQ
Ticker Symbol PYPD
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 278.24% from the latest price.

Stock Forecasts
4 months ago
-2.79%
PolyPid shares are trading higher after the compan... Unlock content with Pro Subscription